Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

personalised medicines

- PMLiVE

Brexit medicine stockpiling could cost £2bn

Cost will be incurred whether a 'no deal' Brexit is avoided or not

- PMLiVE

NICE clears Ipsen’s Cabometyx in first-line kidney cancer

Drug increased PFS by 2.6 months compared to Pfizer’s Sutent

- PMLiVE

UK says firms should stockpile drugs in case of no-deal Brexit

Government also confirms the MHRA will handle UK marketing applications for new medicines

- PMLiVE

Confidence in UK’s post-Brexit healthcare sector on the wane

Only 37% of healthcare workers agree that the UK would be an attractive destination after EU departure

- PMLiVE

Promising more appraisal capacity, NICE revives industry fee idea

Rising workload and shrinking budget making charges inevitable

- PMLiVE

Daily Brief: Sarepta deepens gene therapy investment, NICE changes mind on Besponsa, Digital Medicine company Akili raises $13m

News from pharma, biotech and healthcare

- PMLiVE

Can a post-Brexit UK stay aligned with Europe on clinical research?

There's still no guarantee the UK can keep in step with EU

- PMLiVE

ABPI hits out at ‘punitive’ UK medicines cost controls

Steep rise in charges an 'alarming signal' amid Brexit uncertainty

- PMLiVE

Pharma survey: No Brexit is the best option

But many believe a 'no deal' Brexit most likely outcome

- PMLiVE

As ‘No Deal’ fears grow, pharma can’t rely on transition period

UK could still remain part of EMA 'club' until 2020 - but time is running out

- PMLiVE

EMA cuts back as Brexit staff losses top expectations

Regulator says it faces loss of 30% of staff

- PMLiVE

Sanofi latest to reveal Brexit stockpiling of drugs

Company says UK job losses inevitable in event of hard or no deal Brexit

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links